Erratum: TMEM140 is associated with the prognosis of glioma by promoting cell viability and invasion by Bin Li et al.
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Li et al. Journal of Hematology & Oncology  (2015) 8:101 
DOI 10.1186/s13045-015-0199-0ERRATUM Open AccessErratum: TMEM140 is associated with the
prognosis of glioma by promoting cell viability
and invasion
Bin Li1†, Ming-Zhu Huang2†, Xiao-Qiang Wang1*, Bang-Bao Tao1, Jun Zhong1, Xu-Hui Wang1,
Wen-Chuan Zhang1 and Shi-Ting Li1*It has been brought to our attention that in Fig. two
of the article [1], the immunoblots in the middle
panel were incorrectly labeled as TREM2 instead of
TMEM140. The correct figure is included below (Fig. 1),
in which the immunoblots in the middle panel are
labeled as TMEM140. This labeling correction does not
affect the results or interpretation of the results. We
apologize for this error.
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Fig. 1 Suppressing of TMEM140 expression by RNAi. a TMEM140 expression level in five glioma cell lines was analyzed by RT-PCR (left) and
immunoblot (middle and right). b, c The effect of TMEM140 knockdown through siRNA silencing. The cells were transfected with normal control
or TMEM140-RNAi for 48 h and then subjected to RT-PCR (left) and immunoblot analysis (middle and right) of the TMEM140 expression level. The
representative images for immunoblot are shown in the middle panel, and data from three independent experiments were expressed as the
mean ± S.D. (right panel). Wild type: wild-type cells; normal control: scrambled siRNA transfected cells; RNAi-1, RNAi-2, and RNAi-3: TMEM140-
RNAi-1, -2, and -3 transfected cells (*P < 0.05, **P < 0.01, ***P < 0.001 compared with normal control)
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